Shares of Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) saw strong trading volume on Thursday . 286,014 shares were traded during trading, an increase of 7% from the previous session’s volume of 266,853 shares.The stock last traded at $2.94 and had previously closed at $3.05.

Separately, Maxim Group restated a “buy” rating and set a $17.00 target price on shares of Adamis Pharmaceuticals Corp. in a research note on Monday, June 6th.

The stock’s 50-day moving average is $4.11 and its 200-day moving average is $5.67. The company’s market cap is $46.22 million.

In other news, SVP David J. Marguglio sold 4,860 shares of the firm’s stock in a transaction on Wednesday, May 4th. The stock was sold at an average price of $9.17, for a total transaction of $44,566.20. Following the transaction, the senior vice president now owns 112,227 shares in the company, valued at $1,029,121.59. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP David J. Marguglio sold 4,000 shares of the firm’s stock in a transaction on Monday, May 16th. The shares were sold at an average price of $8.08, for a total value of $32,320.00. Following the transaction, the senior vice president now owns 102,227 shares in the company, valued at approximately $825,994.16. The disclosure for this sale can be found here.

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.